AlphaCentric Advisors LLC increased its position in shares of Amryt Pharma plc (NASDAQ:AMYT – Get Rating) by 44.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 81,000 shares of the company’s stock after acquiring an additional 25,000 shares during the period. AlphaCentric Advisors […]
Amryt Pharma plc (NASDAQ:AMYT – Get Rating) shares saw strong trading volume on Monday . 1,139,608 shares were traded during mid-day trading, an increase of 59% from the previous session’s volume of 716,979 shares.The stock last traded at $14.65 and had previously closed at $14.60. Wall Street Analyst Weigh In Several equities research analysts have […]
Amryt Pharma (NASDAQ:AMYT – Get Rating) and Vincerx Pharma (NASDAQ:VINC – Get Rating) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, risk, valuation, analyst recommendations, profitability, institutional ownership and earnings. Institutional & Insider Ownership 71.3% of Amryt Pharma shares […]
Amryt Pharma plc (NASDAQ:AMYT – Get Rating) was the recipient of a significant growth in short interest in March. As of March 15th, there was short interest totalling 121,200 shares, a growth of 56.2% from the February 28th total of 77,600 shares. Based on an average daily volume of 646,300 shares, the days-to-cover ratio is […]
The British Journal of Dermatology Publishes Results from Amryt’s EASE Phase 3 Trial in Epidermolysis Bullosa DUBLIN, Ireland, and Boston MA, October 25,.